A comprehensive view of Valneva SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

French biotech Valneva, German drug maker IDT Biologika end COVID-19 vaccine deal as demand for vaccinations ebbs; IDT Biologika was to produce bulk vaccine in Germany for Valneva
Published: September 21, 2022 by FiercePharma
Pfizer and Valneva to start late-stage clinical study of experimental VLA15 Lyme disease vaccination with 6,000 participants in US, northern Europe; in June, Pfizer invested US$92.3M in Valneva to support Lyme disease partnership
Published: August 10, 2022 by SeeNews Pharmaceuticals
Pfizer investing US$95M in vaccine company Valneva SE; investment supports strategic partnership between both companies to develop Lyme disease vaccine
Published: June 22, 2022 by Marketline - Deals
Valneva, Pfizer report positive Phase 2 pediatric data for VLA15 Lyme disease vaccine candidate; VLA15 is the only Lyme disease vaccine currently in clinical development, with Lyme disease affecting 476,000 people in US, 130,000 people in Europe annually
Published: April 29, 2022 by Pfizer Inc.
Valneva Scotland announces research funding of up to £20M from Scotland’s national economic development agency; initial grant of £12.5M supports development related to Valneva’s inactivated, whole virus COVID-19 vaccine candidate
Published: February 22, 2022 by Valneva SE

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count